Amgen Hit With US Eylea Suit Ahead Of Looming Biosimilar Date
California-Based Firm Submitted Aflibercept Application Late Last Year
Regeneron is continuing to keep the pressure on would-be biosimilar sponsors for its mammoth Eylea (aflibercept) brand, suing biosimilar sponsor Amgen for alleged patent infringement on the back of a recent favorable verdict over Biocon.
